The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease
Open accessAbstract
BACKGROUND: The advent of bisphosphonates advanced therapy for Paget's disease, but more effective and convenient agents are needed to increase adherence. Zoledronic acid, a bisphosphonate administered as a single intravenous infusion, might meet these needs. METHODS: In two identical, randomized, double-blind, actively controlled trials of 6 months' duration, we compared one 15-minute infusion of 5 mg of zoledronic acid with 60 days of oral risedronate (30 mg per day). The primary efficacy end point was the rate of therapeutic response at six months, defined as a normalization of alkaline phosphatase levels or a reduction of at least 75 percent in the total alkaline phosphatase excess. The results of the studies were pooled. RESULTS: At six months, 96.0 percent of patients receiving zoledronic acid had a therapeutic response (169 of 176), as compared with 74.3 percent of patients receiving risedronate (127 of 171, P<0.001). Alkaline phosphatase levels normalized in 88.6 percent of patients in the zoledronic acid group and 57.9 percent of patients in the risedronate group (P<0.001). Zoledronic acid was associated with a shorter median time to a first therapeutic response (64 vs. 89 days, P<0.001). Higher response rates in the zoledronic acid group were consistent across all demographic, disease-severity, and treatment-history subgroups and with changes in other bone-turnover markers. The physical-component summary score of the Medical Outcomes Study 36-item Short-Form General Health Survey, a measure of the quality of life, increased significantly from baseline at both three and six months in the zoledronic acid group and differed significantly from those in the risedronate group at three months. Pain scores improved in both groups. During post-trial follow-up (median, 190 days), 21 of 82 patients in the risedronate group had a loss of therapeutic response, as compared with 1 of 113 patients in the zoledronic acid group (P<0.001). CONCLUSIONS: A single infusion of zoledronic acid produces more rapid, more complete, and more sustained responses in Paget's disease than does daily treatment with risedronate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1994) · Medical Entomology and Zoology · Cited by 4,156
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Self-citationNew Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Rogers, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033453640 · Cited by 579
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
The pharmacology of bisphosphonates and new insights into their mechanisms of action
Russell, R. G. G., Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., Croucher, P. I., Shipman, C., & Fleisch, H. A. (1999) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650140212 · Cited by 279
The Epidemiology of Paget's Disease in Britain: Is the Prevalence Decreasing?
Prof. Cooper, C., Schafheutle, K., Dennison, E., Kellingray, S., Guyer, P., & Barker, D. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.2.192 · Cited by 246
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone
Siris, E. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.3.961 · Cited by 227
Miller, P. D., Brown, J. P., Siris, E. S., Hoseyni, M. S., Axelrod, D. W., & Bekker, P. J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00062-5 · Cited by 192
Self-citationHarinck, H. I., Papapoulos, S. E., Blanksma, H. J., Moolenaar, A. J., Vermeij, P., & Bijvoet, O. L. (1987) · BMJ · doi:10.1136/bmj.295.6609.1301 · Cited by 183
Reid, I. R., Nicholson, G. C., Weinstein, R. S., Hosking, D. J., Cundy, T., Kotowicz, M. A., Murphy, W. A., Yeap, S., Dufresne, S., Lombardi, A., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00227-6 · Cited by 178
Self-citationSevere Hypocalcemia after Intravenous Bisphosphonate Therapy in Occult Vitamin D Deficiency
Rosen, C. J., & Brown, S. (2003) · New England Journal of Medicine · doi:10.1056/nejm200304103481521 · Cited by 168
Prevalence of Pelvic Paget's Disease of Bone in the United States
Altman, R. D., Bloch, D. A., Hochberg, M. C., & Murphy, W. A. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.3.461 · Cited by 153
Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing
Bauss, F., & Russell, R. G. G. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1612-7 · Cited by 142
Roux, C., Gennari, C., Farrerons, J., Devogelaer, J. P., Mulder, H., Kruse, H. ‐., Picot, C., Titeux, L., Reginster, J.-Y., & Dougados, M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380620 · Cited by 123
Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone
Reid, I. R., Davidson, J. S., Wattie, D. J., Wu, F., Lucas, J., Gamble, G. D., Rutland, M. D., & Cundy, T. (2004) · Bone · doi:10.1016/j.bone.2004.03.023 · Cited by 106
Self-citationPharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption
Green, J. R., & Rogers, M. J. (2002) · Drug Development Research · doi:10.1002/ddr.10071 · Cited by 100
Intravenous Zoledronic Acid in Postmenopausal Women With Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z. D., Richardson, P. A., Trechsel, U., Widmer, A., Devogelaer, J., Kaufman, J., Jaeger, P., et al. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200301000-00020 · Cited by 93
Self-citationRussell, J., Ashok, S., & Koszewski, N. J. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.11.1828 · Cited by 83
Garnero, P., Gineyts, É., Schaffer, A. V., Seaman, J. J., & Delmas, P. D. (1998) · Arthritis & Rheumatism · Cited by 82
Risedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget’s Disease1
Singer, F. R., Clemens, T. L., Eusebio, R. A., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4871 · Cited by 66
Fenton, A. J., Gutteridge, D. H., Kent, G., Price, R. I., Retallack, R. W., Bhagat, C. I., Worth, G. K., Thompson, R. I., Watson, I. G., Barry‐Walsh, C., et al. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb00294.x · Cited by 55
A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone
Fraser, W. D., Stamp, T. C. B., Creek, R. A., Sawyer, J. P. C., & Picot, C. (1997) · Postgraduate Medical Journal · doi:10.1136/pgmj.73.862.496 · Cited by 48
Self-citationRisedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget's Disease
Singer, F. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.6.1906 · Cited by 32
Cited by
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Ruggiero, S. L., Fantasia, J., & Carlson, E. (2006) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2006.06.004 · Cited by 507
Bisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · Pediatrics · doi:10.1542/peds.2006-2023h · Cited by 503
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Metadata
- Authors
- Reid, I. R., Miller, P., Lyles, K., Fraser, W., Brown, J. P., Saidi, Y., Mesenbrink, P., Su, G., Pak, J., Zelenakas, K., Luchi, M., Richardson, P., & Hosking, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09
- Volume
- 353
- Issue
- 9
- Pages
- 898-908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1971365252
- Cited by
- 439
- References
- 24
- FWCI
- 18.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.